Compare AbbVie Inc (ABBV) vs S&P500 ETF (SPY) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
AbbVie Inc vs S&P500 ETF — how do they compare? AbbVie Inc trades at $252.67 (market cap $449.91B), while S&P500 ETF trades at $744.18. The key difference: AbbVie Inc pays a 2.72% dividend while S&P500 ETF pays none. Which is the better fit depends on your goals.
| ABBV | SPY | |
|---|---|---|
Market Cap | $449.91B | — |
Sector | Health | — |
52-Week High | $261.07 | $759.55 |
52-Week Low | $184.85 | $620.34 |
Enterprise Value | $513.38B | — |
Dividend Yield | 2.72% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AbbVie (ABBV) trades at $252.61, down 0.84% on the day, with a bullish technical outlook supported by moving averages and strong support at $248. The company reported revenue of $61.16B in 2025, with EPS beats in recent quarters, though net income margin has trended down to 5.79%. Key growth drivers Skyrizi and Rinvoq are offsetting Humira declines, with positive clinical updates like the Phase 2 ELAHERE data at SGO 2026.
The stock offers a compelling buy case with a consensus price target of $266.33 (5.4% upside) and strong analyst support (68% buy ratings). However, risks include patent cliffs in the 2030s, high debt levels, and margin pressure. Dividend growth is recovering, supporting income investors, but execution on pipeline assets remains critical for sustained expansion.
SPY trades at $747.62, up 0.38% with technical indicators showing mixed signals - moving averages are bullish while oscillators suggest caution. The ETF is approaching key resistance at $750-$758 levels. Recent market sentiment reflects debate between AI-driven growth optimism and concerns about market leverage and valuations.
The outlook remains cautiously optimistic with S&P 500 targets ranging from 8,000-8,800 by year-end, though strategists warn of potential 10-20% corrections. Key risks include excessive market leverage, high valuations, and sector rotation away from tech. Earnings growth and reasonable valuations may support further upside.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About AbbVie Inc
AbbVie is a pharmaceutical company with a strong exposure to immunology and oncology. The firm's top drug, Humira, represents close to half of the company's current profits. The company was spun off from Abbott in early 2013. The recent acquisition of Allergan adds several new drugs in aesthetics and women's health.
Read more on ABBV →About S&P500 ETF
The ETF is designed to track the performance of the securities and the stocks in the S&P 500 Index. To maintain the composition and weightings, the advisor adjusts the ETF from time to time to conform to periodic changes in the index target.
Read more on SPY →
